Patents by Inventor Hans Holmegaard S.o slashed.rensen

Hans Holmegaard S.o slashed.rensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
    Patent number: 6022858
    Abstract: A pharmaceutical formulation comprising a growth hormone pretreated with zinc and optionally lysine or calcium ions shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved formulation at ambient temperature.
    Type: Grant
    Filed: July 23, 1998
    Date of Patent: February 8, 2000
    Assignee: Novo Nordisk A/S
    Inventors: Hans Holmegaard S.o slashed.rensen, Ole Hvilsted Olsen, Lars Thim, Christensen Thorkild, Per Balschmidt
  • Pharmaceutical formulation
    Patent number: 5977069
    Abstract: A pharmaceutical preparation comprising a growth hormone and asparagine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature.
    Type: Grant
    Filed: January 28, 1992
    Date of Patent: November 2, 1999
    Assignee: Novo Nordisk A/S
    Inventor: Hans Holmegaard S.o slashed.rensen
  • Pharmaceutical formulation
    Patent number: 5849700
    Abstract: A pharmaceutical preparation comprising a growth hormone and histidine or a derivative of histidine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature. Crystallization of growth hormone in the presence of histidine or a derivative thereof gives rise to a higher yield of crystals having a higher purity than known methods.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: December 15, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Hans Holmegaard S.o slashed.rensen, Lars Skriver, Annie Rassing Hoelgaard
  • Pharmaceutical formulation
    Patent number: 5849704
    Abstract: A pharmaceutical preparation comprising a growth hormone and histidine or a derivative of histidine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature. Crystallization of growth hormone in the presence of histidine or a derivative thereof gives rise to a higher yield of crystals having a higher purity than known methods.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: December 15, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Hans Holmegaard S.o slashed.rensen, Lars Skriver, Annie Rassing Hoelgaard
  • Pharmaceutical formulation
    Patent number: 5705482
    Abstract: A pharmaceutical formulation comprising a growth hormone and Leu-His-Leu as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved formulation at ambient temperature.
    Type: Grant
    Filed: January 13, 1995
    Date of Patent: January 6, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Thorkild Christensen, Per Balschmidt, Hans Holmegaard S.o slashed.rensen, Ole Hvilsted Olsen, Lars Thim
  • Composition and method comprising growth hormone and leucine
    Patent number: 5654278
    Abstract: A pharmaceutical formulation comprising a growth hormone and leucine shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved formulation at ambient temperature.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: August 5, 1997
    Assignee: Novo Nordisk A/S
    Inventor: Hans Holmegaard S.o slashed.rensen